Masimo to Report Second Quarter 2020 Financial Results after Market Close on Tuesday, July 28
July 14 2020 - 9:00AM
Business Wire
Conference call and webcast to begin at 1:30
p.m. PT (4:30 p.m. ET)
Masimo (NASDAQ: MASI) will release second quarter 2020 financial
results for the period ended June 27, 2020, after the market closes
on Tuesday, July 28, 2020. The conference call to review the
results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be
hosted by Joe Kiani, Chairman and Chief Executive Officer, and
Micah Young, Executive Vice President and Chief Financial
Officer.
A live webcast of the conference call will be available online
from the investor relations page of the Company’s corporate website
at www.masimo.com. The dial-in numbers are (833) 714-0911 for
domestic callers and +1 (778) 560-2686 for international callers.
The reservation code for both dial-in numbers is 2476277. After the
live webcast, the call will be available on Masimo’s website
through August 25, 2020. In addition, a telephonic replay of the
call will be available through August 11, 2020. The replay dial-in
numbers are (800) 585-8367 for domestic callers and +1 (416)
621-4642 for international callers. Please use reservation code
2476277.
About Masimo Masimo (Nasdaq: MASI) is a global medical
technology company that develops and produces a wide array of
industry-leading monitoring technologies, including innovative
measurements, sensors, patient monitors, and automation and
connectivity solutions. Our mission is to improve patient outcomes
and reduce the cost of care. Masimo SET® Measure-through Motion and
Low Perfusion™ pulse oximetry, introduced in 1995, has been shown
in over 100 independent and objective studies to outperform other
pulse oximetry technologies. Masimo SET® has also been shown to
help clinicians reduce severe retinopathy of prematurity in
neonates, improve CCHD screening in newborns, and, when used for
continuous monitoring with Masimo Patient SafetyNet™ in
post-surgical wards, reduce rapid response team activations, ICU
transfers, and costs. Masimo SET® is estimated to be used on more
than 100 million patients in leading hospitals and other healthcare
settings around the world, and is the primary pulse oximetry at 9
of the top 10 hospitals listed in the 2018-19 U.S. News and World
Report Best Hospitals Honor Roll. Masimo continues to refine SET®
and in 2018, announced that SpO2 accuracy on RD SET™ sensors during
conditions of motion has been significantly improved, providing
clinicians with even greater confidence that the SpO2 values they
rely on accurately reflect a patient’s physiological status. In
2005, Masimo introduced rainbow® Pulse CO-Oximetry technology,
allowing noninvasive and continuous monitoring of blood
constituents that previously could only be measured invasively,
including total hemoglobin (SpHb®), oxygen content (SpOC™),
carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), Pleth
Variability Index (PVi®), RPVi™ (rainbow® PVi), and Oxygen Reserve
Index (ORi™). In 2013, Masimo introduced the Root® Patient
Monitoring and Connectivity Platform, built from the ground up to
be as flexible and expandable as possible to facilitate the
addition of other Masimo and third-party monitoring technologies;
key Masimo additions include Next Generation SedLine® Brain
Function Monitoring, O3® Regional Oximetry, and ISA™ Capnography
with NomoLine® sampling lines. Masimo’s family of continuous and
spot-check monitoring Pulse CO-Oximeters® includes devices designed
for use in a variety of clinical and non-clinical scenarios,
including tetherless, wearable technology, such as Radius-7® and
Radius PPG™, portable devices like Rad-67™, fingertip pulse
oximeters like MightySat® Rx, and devices available for use both in
the hospital and at home, such as Rad-97™. Masimo hospital
automation and connectivity solutions are centered around the Iris®
platform, and include Iris Gateway™, Patient SafetyNet, Replica™,
Halo ION™, UniView™, and Doctella™. Additional information about
Masimo and its products may be found at www.masimo.com. Published
clinical studies on Masimo products can be found at
www.masimo.com/evidence/featured-studies/feature/.
ORi and RPVi have not received FDA 510(k) clearance and are not
available for sale in the United States. The use of the trademark
Patient SafetyNet is under license from University HealthSystem
Consortium.
Masimo, SET, Signal Extraction Technology, Improving Patient
Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring
to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet,
PVI are trademarks or registered trademarks of Masimo.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200714005009/en/
Investor Contact: Eli Kammerman (949) 297-7077
ekammerman@masimo.com Media Contact: Evan Lamb (949)
297-3376 elamb@masimo.com
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Masimo (NASDAQ:MASI)
Historical Stock Chart
From Sep 2023 to Sep 2024